“I am over the moon about this,” said Harvard professor Caroline Apovian to us. She was talking about the outstanding topline results with retatrutide reported by Lilly from a phase three study. This is the so-called triple-G agonist that first stunned the world with its phase two results two years ago. In the results yesterday, […]

